This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Dexamethasone implant for diabetic macular oedema

Authoring team

Dexamethasone Implant for Diabetic Macular Oedema

Study evidence found that the dexamethasone implant generally maintained vision at 12 months in eyes with diabetic macular oedema in routine clinical practice (1)

  • treatment with the steroid implant was relatively safe
  • a few eyes on dexamethasone implant treatment had IOP (intraocular pressure) elevation that required treatment and a few others had cataract surgery during the 12 months

NICE state that:

  • dexamethasone intravitreal implant is recommended as an option for treating visual impairment caused by diabetic macular oedema in adults only if their condition has not responded well enough to, or if they cannot have non-corticosteroid therapy

Reference:

  1. Bhandari S et al. Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry. Ophthalmol Ther. 2022 Apr;11(2):797-810.
  2. NICE (September 2022). Dexamethasone intravitreal implant for treating diabetic macular oedema

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.